Oncology Service, Wills Eye Institute Report issue

Academic/Hospital Phase 2

Organization Overview

First Clinical Trial
2009
NCT00857519
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2020

Timeline

NOW
  • Now

Alternative names

Arman Mashayekhi | Jason Hsu, MD | M. Ali Khan, MD

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Dissociative Disorders (Phase 2)

Edema (Phase 2)

Macular Edema (Phase 2)

Melanoma (Phase 2)

Retinal Detachment (Phase 2)

Retinal Diseases (Phase 2)

Uveal Neoplasms (Phase 2)

Vitreoretinopathy, Proliferative (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 3
  • # of Trial APIs: 8